Reduced prostaglandin F2α release from blood mononuclear leukocytes after oral supplementation of ω3 fatty acids: The OmegAD study

Journal of Lipid Research

Volumn 51, Issue 5, 2010, Pages 1179-1185

  Vedin, Inger ^a   Cederholm, Tommy ^b   Freund Levi, Yvonne ^a   Basun, Hans ^b   Hjorth, Erik ^a   Irving, Gerd Faxén ^a   Eriksdotter Jönhagen, Maria ^a   Schultzberg, Marianne ^a   Wahlund, Lars Olof ^a   Palmblad, Jan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

DHA; EPA; LPS; Omega 3 fatty acid; PBMC; PGF; PHA; Prostaglandin

Indexed keywords

11 EPIPROSTAGLANDIN F2 ALPHA; CORN OIL; DOCOSAHEXAENOIC ACID; EPAX 1050TG; FISH OIL; GRANULOCYTE COLONY STIMULATING FACTOR; ICOSAPENTAENOIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 6; LINOLEIC ACID; LIPOPOLYSACCHARIDE; OMEGA 3 FATTY ACID; PHYTOHEMAGGLUTININ; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; PROSTAGLANDIN F2 ALPHA;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CELL STIMULATION; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; BIOSYNTHESIS; BLOOD; CULTURE MEDIUM; DRUG EFFECT; METABOLISM; MIDDLE AGED; MONOCYTE; MONONUCLEAR CELL; ORAL DRUG ADMINISTRATION; T LYMPHOCYTE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CULTURE MEDIA, CONDITIONED; CYTOKINES; DIETARY SUPPLEMENTS; DINOPROST; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MONOCYTES; PHYTOHEMAGGLUTININS; T-LYMPHOCYTES;

EID: 77951085015     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M002667     Document Type: Article

References (46)

1. James, M. J., S. M. Proudman, and L. G. Cleland. 2003. Dietary n-3 fats as adjunctive therapy in a prototypic inflammatory disease: issues and obstacles for use in rheumatoid arthritis. Prostaglandins Leukot. Essent. Fatty Acids. 68: 399-405.
2. Simopoulos, A. P. 2002. Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr. 21: 495-505. (Pubitemid 36026261)
3. Leon, H., M. C. Shibata, S. Sivakumaran, M. Dorgan, T. Chatterley, and R. T. Tsuyuki. 2008. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ. 337: a2931.
4. Barberger-Gateau, P., L. Letenneur, V. Deschamps, K. Peres, J. F. Dartigues, and S. Renaud. 2002. Fish, meat, and risk of dementia: cohort study. BMJ. 325: 932-933. (Pubitemid 35265208)
5. Morris, M. C., D. A. Evans, J. L. Bienias, C. C. Tangney, D. A. Bennett, R. S. Wilson, N. Aggarwal, and J. Schneider. 2003. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol. 60: 940-946. (Pubitemid 36858352)
6. Schaefer, E. J., V. Bongard, A. S. Beiser, S. Lamon-Fava, S. J. Robins, R. Au, K. L. Tucker, D. J. Kyle, P. W. Wilson, and P. A. Wolf. 2006. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch. Neurol. 63: 1545-1550.
7. Freund-Levi, Y., M. Eriksdotter-Jonhagen, T. Cederholm, H. Basun, G. Faxen-Irving, A. Garlind, I. Vedin, B. Vessby, L. O. Wahlund, and J. Palmblad. 2006. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch. Neurol. 63: 1402-1408. (Pubitemid 44547551)
8. Calder, P. C. 2006. Polyunsaturated fatty acids and inflammation. Prostaglandins Leukot. Essent. Fatty Acids. 75: 197-202.
9. de Urquiza, A. M., S. Liu, M. Sjoberg, R. H. Zetterstrom, W. Griffiths, J. Sjovall, and T. Perlmann. 2000. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science. 290: 2140-2144.
10. Zhao, G., T. D. Etherton, K. R. Martin, J. P. Vanden Heuvel, P. J. Gillies, S. G. West, and P. M. Kris-Etherton. 2005. Anti-inflammatory effects of polyunsaturated fatty acids in THP-1 cells. Biochem. Biophys. Res. Commun. 336: 909-917. (Pubitemid 41338355)
11. Spite, M., L. V. Norling, L. Summers, R. Yang, D. Cooper, N. A. Petasis, R. J. Flower, M. Perretti, and C. N. Serhan. 2009. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature. 461: 1287-1291.
12. Fortier, M. A., K. Krishnaswamy, G. Danyod, S. Boucher-Kovalik, and P. Chapdalaine. 2008. A postgenomic integrated view of prostaglandins in reproduction: implications for other body systems. J. Physiol. Pharmacol. 59 ( Suppl 1 ): 65-89.
13. Samuelsson, B., M. Goldyne, E. Granstrom, M. Hamberg, S. Hammarstrom, and C. Malmsten. 1978. Prostaglandins and thromboxanes. Annu. Rev. Biochem. 47: 997-1029.
14. Kobayashi, T., and S. Narumiya. 2002. Function of prostanoid receptors: studies on knockout mice. Prostaglandins Other Lipid Mediat. 68-69: 557-573. (Pubitemid 35247420)
15. de Menezes, G. B., W. G. dos Reis, J. M. Santos, I. D. Duarte, and J. N. de Francischi. 2005. Inhibition of prostaglandin F(2alpha) by selective cyclooxygenase 2 inhibitors accounts for reduced rat leukocyte migration. Inflammation. 29: 163-169.
16. Yu, Y., M. B. Lucitt, J. Stubbe, Y. Cheng, U. G. Friis, P. B. Hansen, B. L. Jensen, E. M. Smyth, and G. A. FitzGerald. 2009. Prostaglandin F2alpha elevates blood pressure and promotes atherosclerosis. Proc. Natl. Acad. Sci. USA. 106: 7985-7990.
17. Goodwin, J. S., A. D. Bankhurst, and R. P. Messner. 1977. Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin- producing suppressor cell. J. Exp. Med. 146: 1719-1734.
18. Wasserman, J., S. Hammarstrom, B. Petrini, H. Blomgren, L. V. von Stedingk, and I. Vedin. 1987. Effects of some prostaglandins and leukotrienes on lymphocytes, monocytes and their activity in vitro. Int. Arch. Allergy Appl. Immunol. 83: 39-43. (Pubitemid 17065740)
19. Spaggiari, G. M., A. Capobianco, H. Abdelrazik, F. Becchetti, M. C. Mingari, and L. Moretta. 2008. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 111: 1327-1333.
20. Betz, M., and B. S. Fox. 1991. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J. Immunol. 146: 108-113.
21. Fedyk, E. R., D. M. Brown, and R. P. Phipps. 1997. PGE2 regulation of B lymphocytes and T helper 1 and T helper 2 cells: induction of inflammatory versus allergic responses. Adv. Exp. Med. Biol. 407: 237-242.
22. Hilkens, C. M., A. Snijders, F. G. Snijdewint, E. A. Wierenga, and M. L. Kapsenberg. 1996. Modulation of T-cell cytokine secretion by accessory cell-derived products. Eur. Respir. J. Suppl. 22: 90s-94s.
23. Hoggatt, J., P. Singh, J. Sampath, and L. M. Pelus. 2009. Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood. 113: 5444-5455.
24. Lemos, H. P., R. Grespan, S. M. Vieira, T. M. Cunha, W. A. Verri, Jr., K. S. Fernandes, F. O. Souto, I. B. McInnes, S. H. Ferreira, F. Y. Liew, et al. 2009. Prostaglandin mediates IL-23/IL-17-induced neutrophil migration in inflammation by inhibiting IL-12 and IFNgamma production. Proc. Natl. Acad. Sci. USA. 106: 5954-5959.
25. Yao, C., D. Sakata, Y. Esaki, Y. Li, T. Matsuoka, K. Kuroiwa, Y. Sugimoto, and S. Narumiya. 2009. Prostaglandin E2-EP4 signaling promotes immune inflammation through TH1 cell differentiation and TH17 cell expansion. Nat. Med. 15: 633-640.
26. Freund-Levi, Y., H. Basun, T. Cederholm, G. Faxen-Irving, A. Garlind, M. Grut, I. Vedin, J. Palmblad, L. O. Wahlund, and M. Eriksdotter-Jonhagen. 2008. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int. J. Geriatr. Psychiatry. 23: 161-169. (Pubitemid 351308496)
27. Irving, G. F., Y. Freund-Levi, M. Eriksdotter-Jonhagen, H. Basun, K. Brismar, E. Hjorth, J. Palmblad, B. Vessby, I. Vedin, L. O. Wahlund, et al. 2009. Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study. J. Am. Geriatr. Soc. 57: 11-17.
28. Vedin, I., T. Cederholm, Y. Freund Levi, H. Basun, A. Garlind, G. Faxen Irving, M. E. Jonhagen, B. Vessby, L. O. Wahlund, and J. Palmblad. 2008. Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. Am. J. Clin. Nutr. 87: 1616-1622. (Pubitemid 351872622)
29. Boberg, M., L. B. Croon, I. B. Gustafsson, and B. Vessby. 1985. Platelet fatty acid composition in relation to fatty acid composition in plasma and to serum lipoprotein lipids in healthy subjects with special reference to the linoleic acid pathway. Clin. Sci. (Lond.). 68: 581-587. (Pubitemid 15103439)
30. Hammarberg, T., M. Hamberg, A. Wetterholm, H. Hansson, B. Samuelsson, and J. Z. Haeggstrom. 2009. Mutation of a critical arginine in microsomal prostaglandin E synthase-1 shifts the isomerase activity to a reductase activity that converts prostaglandin H2 into prostaglandin F2alpha. J. Biol. Chem. 284: 301-305.
31. Mickleborough, T. D., S. L. Tecklenburg, G. S. Montgomery, and M. R. Lindley. 2009. Eicosapentaenoic acid is more effective than docosahexaenoic acid in inhibiting proinflammatory mediator production and transcription from LPS-induced human asthmatic alveolar macrophage cells. Clin. Nutr. 28: 71-77.
32. Razzak, A., C. Aldrich, T. A. Babcock, A. Saied, and N. J. Espat. 2008. Attenuation of iNOS in an LPS-stimulated macrophage model by omega-3 fatty acids is independent of COX-2 derived PGE2. J. Surg. Res. 145: 244-250.
33. Weldon, S. M., A. C. Mullen, C. E. Loscher, L. A. Hurley, and H. M. Roche. 2007. Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid. J. Nutr. Biochem. 18: 250-258.
34. Fujino, H., G. A. Vielhauer, and J. W. Regan. 2004. Prostaglandin E2 selectively antagonizes prostaglandin F2alpha-stimulated T-cell factor/beta-catenin signaling pathway by the FPB prostanoid receptor. J. Biol. Chem. 279: 43386-43391.
35. Harizi, H., and G. Norbert. 2004. Inhibition of IL-6, TNF-alpha, and cyclooxygenase-2 protein expression by prostaglandin E2-induced IL-10 in bone marrow-derived dendritic cells. Cell. Immunol. 228: 99-109.
36. Minakuchi, R., M. C. Wacholtz, L. S. Davis, and P. E. Lipsky. 1990. Delineation of the mechanism of inhibition of human T cell activation by PGE2. J. Immunol. 145: 2616-2625. (Pubitemid 20374587)
37. Scales, W. E., S. W. Chensue, I. Otterness, and S. L. Kunkel. 1989. Regulation of monokine gene expression: prostaglandin E2 suppresses tumor necrosis factor but not interleukin-1 alpha or beta-mRNA and cell-associated bioactivity. J. Leukoc. Biol. 45: 416-421.
38. Roman, A. S., J. Schreher, A. P. Mackenzie, and P. W. Nathanielsz. 2006. Omega-3 fatty acids and decidual cell prostaglandin production in response to the inflammatory cytokine IL-1beta. Am. J. Obstet. Gynecol. 195: 1693-1699.
39. Krause, P., M. Bruckner, C. Uermosi, E. Singer, M. Groettrup, and D. F. Legler. 2009. Prostaglandin E(2) enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells. Blood. 113: 2451-2460.
40. De Smedt-Peyrusse, V., F. Sargueil, A. Moranis, H. Harizi, S. Mongrand, and S. Laye. 2008. Docosahexaenoic acid prevents lipopolysaccharide-induced cytokine production in microglial cells by inhibiting lipopolysaccharide receptor presentation but not its membrane subdomain localization. J. Neurochem. 105: 296-307. (Pubitemid 351490003)
41. Trebble, T. M., S. A. Wootton, E. A. Miles, M. Mullee, N. K. Arden, A. B. Ballinger, M. A. Stroud, G. C. Burdge, and P. C. Calder. 2003. Prostaglandin E2 production and T cell function after fish-oil supplementation: response to antioxidant cosupplementation. Am. J. Clin. Nutr. 78: 376-382.
42. Rees, D., E. A. Miles, T. Banerjee, S. J. Wells, C. E. Roynette, K. W. Wahle, and P. C. Calder. 2006. Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. Am. J. Clin. Nutr. 83: 331-342. (Pubitemid 44713195)
43. Arntzen, K. J., O. L. Brekke, L. Vatten, and R. Austgulen. 1998. Reduced production of PGE2 and PGF2 alpha from decidual cell cultures supplemented with N-3 polyunsaturated fatty acids. Prostaglandins Other Lipid Mediat. 56: 183-195.
44. Hoshino, T., T. Namba, M. Takehara, T. Nakaya, Y. Sugimoto, W. Araki, S. Narumiya, T. Suzuki, and T. Mizushima. 2009. Prostaglandin E2 stimulates the production of amyloid-beta peptides through internalization of the EP4 receptor. J. Biol. Chem. 284: 18493-18502.
45. Hull, M., B. Muksch, R. S. Akundi, A. Waschbisch, J. J. Hoozemans, R. Veerhuis, and B. L. Fiebich. 2006. Amyloid beta peptide (25-35) activates protein kinase C leading to cyclooxygenase-2 induction and prostaglandin E2 release in primary midbrain astrocytes. Neurochem. Int. 48: 663-672.
46. Serhan, C. N., N. Chiang, and T. E. Van Dyke. 2008. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8: 349-361.